Sinus congestion and increased difficulty breathing are prominent symptoms of allergic upper airway inflammation in humans. In order to test the efficacy of putative drugs that might ameliorate these symptoms, we developed a model of sinus congestion in the guinea pig (GP), which has relevant histamine-driven allergic similarities to humans. GP's were administered ragweed pollen (RWP; 0-50ug) intranasally once per day, for 5 days, to determine both the dose-response relationship of sinus airway inflammation, and the maximal effect dose against which to test intranasal anti-inflammatory steroids, dexamethasone, mometasone, and fluticasone. After administration of RWP with and without steroid treatment, sinus cavity filling was measured as an index of allergic sinus congestion, and compared across treatments by ANOVA. Significant concentration-dependent increments in sinus congestion were observed with increasing concentrations of RWP, to levels that indicated up to 80% sinus occlusion at the highest concentrations of RWP tested (P<0.05). Significant concentration-dependent reductions of sinus congestion were produced by treatment with all three steroids, such that all steroids tested were able to completely abolish sinus congestion, to levels similar to RWP-vehicle-treated controls (n.s.). These results indicate proof-of-concept for this GP sinus congestion model, as being reliable for both measurement of the induction of allergic sinus congestion associated with upper airway inflammation, and its reduction with anti-inflammatory compounds typically used to treat nasal congestion both therapeutically (fluticasone, mometasone), and experimentally (dexamethasone). We conclude that this model should be suitable for evaluating novel compounds for developed for the treatment of allergic sinus inflammation and congestion.
Read full abstract